[1] Ahn GO, Tseng D, Liao CH, Dorie MJ, Czechowicz A Brown JM. Inhibition of Mac-1 (CD11b/CD18) enhances tumour response to radiation by reducing myeloid cell recruitment. Proc Natl Acad Sci U S A 2010;107:8363-8368.
[2] Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13:1050-1059.
[3] Barbetta A, Nobel TB, Sihag S, et al. Neutrophil to Lymphocyte Ratio as Predictor of Treatment Response in Oesophageal Squamous Cell Cancer. Ann Thorac Surg 2018;106:864-871.
[4] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
[5] Burnette BC, Liang H, Lee Y, et al. The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon-Dependent Innate and Adaptive Immunity. Cancer Res 2011;71:2488-2496.
[6] Chao YK, Tseng CK, Wen YW, et al. Using Pretreatment Tumour Depth and Length to Select Oesophageal Squamous Cell Carcinoma Patients for Nonoperative Treatment After Neoadjuvant Chemoradiotherapy. Annals of Surgical Oncology 2013;20:3000-3008.
[7] Chen JZ, Guo H, Zhai TT, et al. Radiation dose escalation by simultaneous modulated accelerated radiotherapy combined with chemotherapy for oesophageal cancer: a phase II study. Oncotarget 2016;7:22711-22719.
[8] Chen MF, Chen PT, Kuan FC Chen WC. The Predictive Value of Pretreatment Neutrophil-To-Lymphocyte Ratio in Oesophageal Squamous Cell Carcinoma. Ann Surg Oncol 2019;26:190-199.
[9] Chowdhary M, Switchenko JM, Press RH, et al. Post-treatment neutrophil-to-lymphocyte ratio predicts for overall survival in brain metastases treated with stereotactic radiosurgery. J Neuro-Oncol 2018;139:689-697.
[10] Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced oesophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623-1627.
[11] Cox S, Hurt C, Grenader T, Mukherjee S, Bridgewater J Crosby T. The prognostic value of derived neutrophil to lymphocyte ratio in ooesophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol 2017;125:154-159.
[12] Cremonesi M, Garibaldi C, Timmerman R, et al. Interim (18)F-FDG-PET/CT during chemo-radiotherapy in the management of ooesophageal cancer patients. A systematic review. Radiother Oncol 2017;125:200-212.
[13] Davuluri R, Jiang W, Fang P, et al. Lymphocyte Nadir and Oesophageal Cancer Survival Outcomes After Chemoradiation Therapy. Int J Radiat Oncol Biol Phys 2017;99:128-135.
[14] Diakos CI, Charles KA, McMillan DC Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol 2014;15:E493-E503.
[15] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer 2009;45:228-247.
[16] Fang P, Jiang W, Davuluri R, et al. High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in oesophageal cancer. Radiother Oncol 2018;128:584-590.
[17] Fareed KR, Kaye P, Soomro IN, et al. Biomarkers of response to therapy in oesophago-gastric cancer. Gut 2009;58:127-143.
[18] Feng X, Li L, Wu J, et al. Complete Blood Count Score Model Integrating Reduced Lymphocyte-Monocyte Ratio, Elevated Neutrophil-Lymphocyte Ratio, and Elevated Platelet-Lymphocyte Ratio Predicts Inferior Clinical Outcomes in Adult T-Lymphoblastic Lymphoma. Oncologist 2019.
[19] Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the oesophagus. N Engl J Med 1992;326:1593-1598.
[20] Ishihara R, Yamamoto S, Iishi H, et al. Factors predictive of tumour recurrence and survival after initial complete response of oesophageal squamous cell carcinoma to definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys 2010;76:123-129.
[21] Khunger M, Patil PD, Khunger A, et al. Post-treatment changes in haematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients. PLoS One 2018;13:e0197743.
[22] Knight K, Wade S Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 2004;116 Suppl 7A:11S-26S.
[23] Kwee RM. Prediction of Tumour Response to Neoadjuvant Therapy in Patients with Oesophageal Cancer with Use of F-18 FDG PET: A Systematic Review. Radiology 2010;254:707-717.
[24] Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumour require CD8+ T cells: changing strategies for cancer treatment. Blood 2009;114:589-595.
[25] Lee YJ, Lee SB, Beak SK, et al. Temporal changes in immune cell composition and cytokines in response to chemoradiation in rectal cancer. Sci Rep 2018;8:7565.
[26] Liang H, Deng L, Hou Y, et al. Host STING-dependent MDSC mobilization drives extrinsic radiation resistance. Nat Commun 2017;8:1736.
[27] Lin AJ, Rao YJ, Chin RI, et al. Post-operative radiation effects on lymphopenia, neutrophil to lymphocyte ratio, and clinical outcomes in palatine tonsil cancers. Oral Oncol 2018;86:1-7.
[28] Mao Y, Chen D, Duan S, et al. Prognostic impact of pretreatment lymphocyte-to-monocyte ratio in advanced epithelial cancers: a meta-analysis. Cancer Cell Int 2018;18:201.
[29] Miao C, Zhu S, Pan H, Cao X, Yuan S Hu X. Combined neutrophil-platelet score and haemoglobin level predict survival in oesophageal squamous cell carcinoma patients treated with chemoradiotherapy. Oncotarget 2017;8:87971-87979.
[30] Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for oesophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1167-1174.
[31] Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumour immunotherapy. J Exp Med 2006;203:1259-1271.
[32] Suh KJ, Kim SH, Kim YJ, et al. Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody. Cancer Immunol Immun 2018;67:459-470.
[33] Swann JB Smyth MJ. Immune surveillance of tumours. J Clin Invest 2007;117:1137-1146.
[34] Templeton AJ, Ace O, McNamara MG, et al. Prognostic role of platelet to lymphocyte ratio in solid tumours: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2014;23:1204-1212.
[35] Templeton AJ, McNamara MG, Seruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumours: a systematic review and meta-analysis. J Natl Cancer Inst 2014;106:dju124.
[36] Yodying H, Matsuda A, Miyashita M, et al. Prognostic Significance of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Oncologic Outcomes of Oesophageal Cancer: A Systematic Review and Meta-analysis. Ann Surg Oncol 2016;23:646-654.
[37] Yoo EJ, Park JC, Kim EH, et al. Prognostic value of neutrophil-to-lymphocyte ratio in patients treated with concurrent chemoradiotherapy for locally advanced oesophageal cancer. Dig Liver Dis 2014;46:846-853.
[38] Zenda S, Hironaka S, Boku N, et al. Impact of haemoglobin level on survival in definitive chemoradiotherapy for T4/M1 lymph node oesophageal cancer. Dis Oesophagus 2008;21:195-200.
[39] Zhang WZ, Chen JZ, Li DR, et al. Simultaneous modulated accelerated radiation therapy for oesophageal cancer: a feasibility study. World J Gastroenterol 2014;20:13973-13980.
[40] Zhou XL, Li YQ, Zhu WG, et al. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for patients with locally advanced oesophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Sci Rep-Uk 2017;7.